A llergic diseases are caused by hypersensitivity reaction of immune responses and are commonly classified according to the type of immune responses. The Th2 immune response is involved in IgE production and mediates type I allergic responses (so-called immediate hypersensitivity), which are due to mast cell activation induced by the crosslinking of FcεRI with an IgE immune complex (1, 2) . In contrast, the Th1 immune response leads to delayed-type hypersensitivity through the production of proinflammatory cytokines from Th1 and CD8 + T cells. Imbalance in the numbers of Th1 and Th2 cells is responsible for many allergic inflammatory disorders and correction of the imbalance may ameliorate allergic inflammation. For example, the administration of recombinant IFN-g or IL-12, which induce the polarization of CD4 + naive Th cells into Th1 cells, attenuates allergic airway inflammation (3, 4) .
Allergic contact dermatitis (ACD) is one of the most common skin diseases, affecting 15-20% of the general population worldwide. Contact hypersensitivity (CHS) is the most frequently used murine model of human ACD (5) . The pathogenesis of CHS is based on delayed-type hypersensitivity, which is mediated mainly by Th1 immune responses. The CHS reaction is divided into the sensitization and elicitation phases. Ag-specific Th1 cell clones differentiate from naive CD4 + Th cells during the sensitization phase; later on, re-exposure to Ag activates Th1 and CD8 + T cells, thus inducing cytokine-mediated inflammation during the elicitation phase. Recent evidence has demonstrated that regulatory T cells, Th17 cells, and dermal dendritic cells (DC) also play important roles in the pathogenesis of CHS (5) . Moreover, CHS reactions are attenuated in mice deficient in CD28, OX40L, and LFA-1 (6) (7) (8) , suggesting that these costimulatory molecules are involved in the development of CHS.
Th1 cells produce IFN-g, IL-2, and TNF-a and are involved in cellular immune responses against intracellular pathogens. The differentiation of Th1 cells from naive CD4 + T cells is driven mainly by IL-12 produced by APCs. IL-12-mediated signaling in CD4 + T cells activates STAT4, which induces IFN-g production (9) . IFN-g promotes the phosphorylation of STAT1 by binding to the receptor for IFN-g that is expressed on CD4 + T cells, resulting in upregulation of T-bet, a master regulator of Th1 development. Thus, Th1 development is reinforced by autocrine IFN-g via the STAT1 and T-bet signaling pathways in a positive-feedback manner (10, 11) . However, although IL-12-deficient mice show severely impaired Th1 responses, they still carry low levels of Th1 cells, suggesting that these cells might alternatively be developed through an IL-12-independent mechanism (12) .
CD155, initially identified as a receptor for poliovirus in humans (13) , is a member of poliovirus receptor-related (PRR) family of adhesion molecules, which consists of CD111 (nectin-1/PRR-1), CD112 (nectin-2/PRR-2), nectin-3 (PRR-3), and nectin-4 (PRR-4). The CD155 transcript is ubiquitously expressed in most organs in both humans and mice (13) (14) (15) and on various hematopoietic cells in mice, including T cells, macrophages, and DC (16) . CD155 binds to another PRR family member, nectin-3, as well as the matrix protein vitronectin, thereby mediating cell-cell or cell-matrix adhesion, respectively, and cell migration (17) . Additionally, CD155 is a ligand for the Ig-like receptors DNAM-1 (CD226), Tactile (CD96), and T cell immunoreceptor with Ig and ITIM domains (TIGIT) on T cells and NK cells (18) (19) (20) (21) (22) . Mice deficient in CD155 show diminished humoral immune responses and thymic retention of mature CD8 + cells (16, (23) (24) (25) . Although several studies have demonstrated various functions of CD155, particularly on nonhematopoietic cells, the role of CD155 in lymphocyte function remains undefined.
In this study, we investigated the role of CD155 in lymphocyte function and immune responses. We show that CD155-mediated signaling plays an important role in the pathogenesis of contact hypersensitivity.
Materials and Methods
Mice C57BL/6 and BALB/c mice were purchased from Clea Japan (Tokyo, Japan). Ifng 2/2 mice and Rag1 2/2 mice were purchased from The Jackson Laboratory (Bar Harbor, ME). CD155-deficient (Pvr 2/2 ) mice were generated as described (16) and were crossed with OT-II transgenic (Tg) mice (26) . DNAM-1-deficient (Cd226 2/2 ) mice generated as described (27) were crossed with Rag1 2/2 mice. All mice were housed and bred under specific pathogen-free conditions at the Laboratory Animal Resource Center (University of Tsukuba, Ibaraki, Japan). All animal experiments were performed according to the guidelines of the Animal Ethics Committee of the Laboratory Animal Resource Center, University of Tsukuba.
Human samples
Human peripheral blood was obtained from healthy volunteers after obtaining informed consent. Human cord blood was purchased from the RIKEN BioResource Center (Ibaraki, Japan). All experiments with samples of human blood were approved by the Ethics Review Board of the University of Tsukuba.
Abs and reagents
Anti-mouse CD3 (145-2C11), CD4 (RM4-5), CD8 (53-6.7), CD28 (37.51), CD62L (MEL-14), CD44 (IM7), B220 (RA3-6B2), CD49b (DX5), CD11c (HL3), CD11b (M1/70), Ly6G (1A8), Siglec-F (E50-2440), IFN-g receptor a-chain (IFN-gRa; GR20), IFN-g (XMG-1.2), IL-4 (11B11), IL-17A (TC11-18H10.1), and IL-12 (C17.8) mAbs; anti-human CD3 (UCHT1), CD4 (RPA-T4), CD8 (RPA-T8), CD19 (HIB19), CD56 (B159), CD28 (CD28.2), CD45RA (HI100), CD45RO (UCHL1), and CD44 (G44-26) mAbs; isotype-matched control Abs; and secondary Abs and fluoresceinconjugated streptavidin were purchased from BD Biosciences (San Jose, CA). Anti-human CD14 (TUK4) mAb was purchased from Miltenyi Biotec (Bergisch Gladbach, Germany). Anti-mouse IFN-gRa (2E2) was purchased by BioLegend (San Diego, CA). Anti-mouse T-bet (4B10) mAbs were purchased from eBioscience (San Diego, CA). Anti-mouse p-STAT1 (42H3) mAb and STAT1, IkBa polyclonal Abs, and anti-a-tubulin mAb were purchased from Cell Signaling Technology (Danvers, MA, USA), and anti-mouse NF-kB polyclonal Abs and anti-lamin B polyclonal Abs were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-mouse b-actin (AC15) mAb was purchased from Sigma-Aldrich (St. Louis, MO). For ELISA, anti-mouse IFN-g (AN-18), IL-2 (JES6-1A2), and IgE (R35-72) mAbs were used as capture Abs, and biotinylated antimouse IFN-g (R4-6A2), IL-2 (JES6-5H4), and IgE (R35-118) mAbs were used as detection Abs; these mAbs all were purchased from BD Biosciences. Streptavidin-conjugated HRP was purchased from GE Healthcare Biosciences (Little Chalfont, U.K.). Anti-mouse CD155 mAb (TX56, rat IgG2a), which blocks the interaction between CD155 and its ligand DNAM-1 (28), anti-mouse DNAM-1 mAb (TX42, rIgG2a), and antihuman CD155 mAb (TX24) were generated in our laboratory (27, 29) . Recombinant mouse and human IL-2 were purchased from BD Biosciences. NF-kB inhibitor JSH-23 was purchased from Merck Millipore (Darmstadt, Germany)
Flow cytometry
Flow cytometric analysis and cell sorting were performed by using FACSCalibur, LSRFortessa, and FACSAria flow cytometers (BD Biosciences). FlowJo software (Tree Star, Ashland, OR) was used for data analysis.
Isolation of CD4
+ T cells 2 CD4 + T cells were sorted from mouse spleens or human cord blood, respectively, by using FACSAria (BD Biosciences).
Stimulation of CD4 + T cells
To examine tyrosine phosphorylation of CD155, CD4 + T cells were stimulated with anti-CD155 mAb or control Ig (cIg; 10 mg/ml) and then cross-linked with anti-rat IgG secondary Ab (10 mg/ml). For proliferation assays, CD4 + T cells were stimulated for 48 h with plate-bound anti-CD3 mAb and either plate-bound rat IgG2a isotype control or anti-CD155 mAb (20 mg/ml). CFSE-labeled CD4 + T cells were stimulated for 48 h with plate-bound anti-CD3 mAb and either plate-bound rat IgG2a isotype control or anti-CD155 mAb (20 mg/ml). CFSE dilution was measured by flow cytometry. For analysis of IkBa, CD4 + T cells were stimulated with plate-bound anti-CD3 and anti-CD155 mAbs. In the case of Erk and NFkB, CD4 + T cells were stimulated with soluble anti-CD3 and anti-CD155 mAbs, followed by cross-linking with secondary Abs. Mouse and human CD4 + naive T cells were stimulated for 6 d with plate-bound anti-CD3 mAb (1 mg/ml) and anti-CD155 mAb (20 mg/ml) in the presence of IL-2 (20 ng/ml). For coculture assays, splenocytes were treated with 50 mg mitomycin C. Naive CD4 + T cells (10 5 ) and the splenocytes (2 3 10 6 ) were cocultured for 6 d with OVA 323-339 peptide (1 mM) in the presence or absence of neutralizing anti-IL-12 mAb or anti-IFN-g mAb (40 mg/ml).
Analysis of intracellular cytokines
Cells (10 5 -10 6 /ml) were stimulated with PMA (50 ng/ml) plus ionomycin (500 ng/ml) for 2 h, after which brefeldin A (10 mg/ml; Sigma-Aldrich) was added and cells were cultured for another 2 h. Cells then were harvested, resuspended, stained for intracellular cytokines (Fix and Perm Kit, Invitrogen) according to the manufacturer's instructions, and analyzed by flow cytometry.
ELISA
The concentration of mouse IFN-g and IL-2 in culture supernatants and IgE, IgG1, and IgG2a in sera were measured by ELISA using capture and detection mAbs against mouse IFN-g, IL-2, and IgE. Mouse IL-4 and human IFN-g and IL-4 concentrations were measured by using ELISA kits from BD Biosciences, and mouse and human IL-17A levels were measured by using ELISA kits from R&D Systems; all assays were performed according to the manufacturers' instructions.
Biochemistry
After respective stimulations as described in Materials and Methods, cells were lysed by using a buffer containing 1% Nonidet P-40, protease inhibitors, and phosphatase inhibitors, as described (30) . Total cell lysates were immunoprecipitated by using control Ab or anti-CD155 mAb. Proteins were separated by SDS-PAGE under nonreducing conditions, immunoblotted by using anti-phosphotyrosine (4G10) (0.3 mg/ml) Ab, and reblotted with anti-CD155 mAb (2 mg/ml). For analysis, IkBa and NF-kBstimulated cells were lysed by using 1% Nonidet P-40 lysis buffer as described above, or by a cytoplasmic and nuclear extraction kit (Invent, Eden Prairie, MN), respectively, and immunoblotted with appropriate Abs, according to the manufacturer's instructions.
Quantitative RT-PCR
Total RNA was isolated from cell pellets by using Isogen reagent (Nippon Gene, Tokyo, Japan). For reverse transcription, we used 2 mg total RNA and a final volume of 20 ml with a high-capacity cDNA reverse transcription kit (Applied Biosystems, Carlsbad, CA). Real-time PCR analysis of Tbx21, Gata3, Rorc, Foxp3, and Ifng was performed by using an ABI 7500 sequence detector (Applied Biosystems), the Power SYBR Green PCR master mix (Applied Biosystems), and appropriate primers. Primer sequences of the target genes are: Tbx21, forward, 59-AGC AAG GAC GGC GAA TGT T-39, reverse, 59-GGG TGG ACA TAT AAG CGG TTC-39; Gata3, forward, 59-TTA TCA AGC CCA AGC GAA GG-39, reverse, 59-CAT TAG CGT TCC TCC TCC AGA G-39; Rorc, forward, 59-GGA GGA CAG GGA GCC AAG TT-39, reverse, 59-CCG TAG TGG ATC CCA GAT GAC T-39; Foxp3, forward, 59-CCC ATC CCC AGG AGT CTT G-39, reverse, 59-ACC ATG ACT AGG GGC ACT GTA-39; Ifng, forward, 59-ACA GCA AGG CGA AAA AGG ATG-39, reverse, 59-TGG TGG ACC ACT CGG ATG A-39; Actb, forward, 59-ACT GTC GAG TCG CGT CCA-39, reverse, 59-GCA GCG ATA TCG TCA TCC AT-39. The b-actin level was measured as an internal control to normalize data. The thermal cycling conditions comprised an initial denaturation step at 95˚C for 10 min, followed by 40 cycles at 95˚C for 15 s and 60˚C for 1 min. The mRNA level was determined relative to that in mouse spleen. All values were determined in triplicate. total) to the inner and outer sides of the left ear and of ethanol only to the right ear. Response was assessed by using a digital thickness gauge (G-1A; Ozaki, Tokyo, Japan) to measure ear thickness. Net ear swelling was calculated as the difference between the thickness of the right and left ears of each mouse. For the transfer model, either WT or Pvr 2/2 CD4 + T cells (10 7 ) and WT CD8 + T cells (10 6 ) were injected i.v. into Rag1 2/2 or Rag1 2/2 Cd226 2/2 mice. One week after transfer, CHS was induced as described above. Five days after sensitization, draining lymph nodes were harvested, and cytokine production was analyzed by flow cytometry. For treatment of Ab, mice were injected i.v. with anti-CD155 mAb (TX56) or control mAb (MP Biomedicals, Solon, OH) at 2 h prior to sensitization (anti-CD155 dose, 1.0 mg) or challenge (0.5 mg).
Induction of eosinophilic airway inflammation
WT and Pvr 2/2 BALB/c mice were injected i.p. with OVA (100 mg) plus aluminum hydroxide (alum) on days 0 and 7. On days 14, 15, and 16, these mice were challenged intranasally with OVA (10 mg in PBS) or PBS alone. On day 18, the numbers of total cells and eosinophils in bronchoalveolar lavage fluid were determined by using flow cytometry. Serum IgE, IgG1, and IgG2a levels on days 0 and 14 were measured by using ELISA.
Histology
Mouse ears and lungs were fixed with formalin and then stained with H&E for histopathologic examination by light microscopy (3200 objective). 
Statistical analysis
Statistical analyses were performed by using the unpaired or paired Student t test (GraphPad Prism 5, GraphPad Software, La Jolla, CA). A p value ,0.05 was considered statistically significant.
Results

CD155 mediates a costimulatory signal in CD4 + T cells
To analyze the function of CD155 in immune responses, we first investigated the expression profile of CD155 on spleen cells. CD155 was broadly expressed on both myeloid and lymphoid lineage cells. Of note, CD155 was expressed most strongly on CD4 + T cells (Supplemental Fig. 1A) . Stimulation of CD4 + T cells with plate-bound anti-CD3 plus anti-CD28 mAbs further augmented the expression of CD155 (Supplemental Fig. 1B) . Therefore, we focused our present study on the role of CD155 in immune responses by CD4 + T cells. CD4 + T cells purified from the spleen were stimulated with anti-CD155 mAb. Immunoblot analysis demonstrated that CD155 became tyrosine phosphorylated after stimulation (Fig. 1A) , suggesting that CD155 is a signal-transducing molecule in CD4 + T cells. We next examined whether CD155 mediates a costimulatory signal in CD4 + T cells. Erk is phosphorylated after stimulation of the TCR with a cognate Ag or anti-CD3 mAb (31) . Stimulation of CD4 + T cells with anti-CD155 together with anti-CD3 mAb augmented Erk phosphorylation as early as 2 min after stimulation, compared with stimulation with control mAb and anti-CD3 mAb (Fig. 1B) . Furthermore, stimulation of CD4 + T cells with anti-CD155 mAb plus anti-CD3 mAb markedly increased activation of NF-kB, as determined by translocation of p65 NF-kB from the cytoplasm into the nuclei (Fig. 1C) , increased number of activated CD4 + T cells (Fig. 1D ), augmented proliferation of CD4 + T cells (Fig. 1E) , and increased IL-2 production by CD4 + T cells (Fig. 1F) , compared with stimulation with control mAb plus anti-CD3 mAb. In contrast, stimulation with anti-CD155 mAb plus anti-CD3 mAb did not augment the proliferation of CD155-deficient (Pvr 2/2 ) CD4 + T cells (Fig. 1G ). Taken together, these results suggest that CD155 is a costimulatory molecule in CD4 + T cells.
CD155 mediates IL-12-independent Th1 development from naive CD4 + T cells
We next investigated whether CD155-mediated signal is involved in development of Th cell subsets. Naive CD4 + T cells, prepared by sorting CD3 + CD4 + CD62L hi CD44 dull cells from the spleen by using flow cytometry, were stimulated for 6 d with anti-CD3 mAb and either plate-bound anti-CD155 or control mAb in the presence of IL-2 and analyzed for cytokine production. Stimulation with anti-CD155 and anti-CD3 mAbs significantly increased the production of IFN-g but not IL-4 or IL-17 by CD4 + T cells, compared with stimulation with control mAb and anti-CD3 mAb ( Fig. 2A,  2B ). These results suggest that CD155 is involved in the development of Th1 cells. Because the in vitro Th1 differentiation assay was free from IL-12, these results suggest that CD155 is involved in IL-12-independent Th1 development from naive CD4 + T cells. indicating that CD155 plays an important role in Th1 development when naive CD4 + T cells are stimulated by using a cognate Ag and APCs that express DNAM-1, a natural ligand for CD155 (Fig. 2C, Supplemental Fig. 1C) . In contrast, IL-4 and IL-17 production was comparable between Pvr +/+ and Pvr 2/2 CD4 + T cells. The addition of a neutralizing anti-IL-12 mAb into the assay still permitted significantly greater IFN-g production from Pvr +/+ CD4 + T cells than from Pvr 2/2 CD4 + T cells (Fig. 2C ), indicating that CD155 does not necessarily require IL-12 to induce Th1 development. Alternatively, the generation of Th1 cells from naive CD4 + T cells after stimulation with anti-CD3 and anti-CD155 was comparable to that after stimulation with anti-CD3 http://www.jimmunol.org/ plus control Ab in the presence of exogenous IL-12 and anti-IL-4 (Th1 condition) (Supplemental Fig. 2A) 
CD4
+ T cells and APCs under the Th1 condition (Supplemental Fig. 2B ), indicating that CD155 is not necessarily required for Th1 differentiation from naive CD4 + T cells when in the presence of adequate exogenous IL-12.
The transcription of Tbx21, which encodes T-bet, was upregulated in CD4 + T cells after stimulation with anti-CD155 and anti-CD3 mAbs (Fig. 2D) . In contrast, these cells showed downregulation of Gata3, a master regulator of Th2 development (Fig. 2D) . There was no difference in expression of Rorc, which encodes retinoic acidrelated orphan receptor gt, and Foxp3, master regulators of Th17 and regulatory T cells, respectively, between CD4 + T cells stimulated with anti-CD155 mAb plus anti-CD3 mAb and those stimulated with control mAb and anti-CD3 mAb (Fig. 2D) . Taken together, CD155-mediated signal is involved in IL-12-independent Th1 development.
CD155 mediates IFN-g-dependent Th1 development from naive CD4 + T cells
We next investigated the molecular mechanism of Th1 development induced by CD155-mediated signaling. Because STAT1 activation upregulates T-bet expression and Th1 development (10), we examined whether CD155 mediates STAT1 phosphorylation.
Although stimulation of CD4 + T cells with anti-CD3 mAb plus control mAb moderately induced STAT1 phosphorylation, costimulation with plate-bound anti-CD155 together with anti-CD3 mAbs markedly increased both the expression and phosphorylation of STAT1 (Fig. 3A) , suggesting that CD155-mediated Th1 development is dependent on the STAT1 pathway. Because IFN-g also activates STAT1, we investigated whether CD155-mediated activation of STAT1 required IFN-g. STAT1 expression and phosphorylation were negligible in Ifng 2/2 CD4 + T cells after stimulation with anti-CD3, regardless of whether anti-CD155 mAb was included (Fig. 3A) , indicating that the CD155-associated induction of STAT1 expression and phosphorylation is dependent on IFN-g. Moreover, CD155-mediated upregulation of T-bet expression was undetectable in Ifng 2/2 CD4 + T cells (Fig. 3B) . A neutralizing anti-IFN-g mAb decreased IFN-g production from both Pvr +/+ and Pvr 2/2 OT-II CD4 + T cells at the same level after coculture with WT splenocytes loaded with OVA peptide (Fig. 3C) . These results suggest that CD155-mediated STAT1 phosphorylation and subsequent Th1 development were dependent on IFN-g.
We therefore investigated whether CD4 + T cells produced IFN-g before STAT1 phosphorylation after stimulation with anti-CD155 mAb. We found that Ifng transcript was significantly upregulated in naive CD4 + T cells just 10 h after stimulation with plate-bound anti-CD155 mAb and anti-CD3 mAb compared with stimulation with control mAb and anti-CD3 mAb (Fig. 3D) . We also found that the expression of IFN-gRa on CD4 + T cells was comparable regardless of stimulation with anti-CD155 mAb, as analyzed by using an anti-IFN-gRa mAb 2E2 (Fig. 3E) . However, when we used GR20 anti-IFN-gRa mAb, which, unlike 2E2 mAb, competes with IFN-g for binding to IFN-gRa, GR20 mAb binding was significantly suppressed on CD4 + T cells after stimulation with anti-CD155 mAb and anti-CD3 mAb, compared with stimulation with control mAb and anti-CD3 mAb (Fig. 3E) , suggesting that autocrine IFN-g bound to IFN-gRa on CD4 + T cells stimulated with anti-CD155 mAb and anti-CD3 mAb significantly more than on CD4 + T cells stimulated with control mAb and anti-CD3 mAb before STAT1 phosphorylation. Taken together, these results indicated that CD155-mediated signal induced STAT1-independent production of IFN-g, triggering the positive feed- back of IFN-g-dependent STAT1 phosphorylation and Th1 development. It remains undetermined how CD155 upregulates STAT1-independent IFN-g expression. However, we found that stimulation with anti-CD155 and anti-CD3 mAbs induced degradation of IkBa significantly more than that with control mAb and anti-CD3 mAbs even in the absence as well as in the presence of IFN-g (Fig. 3F) . Moreover, the expression of Ifng gene was significantly decreased in the presence of NF-kB inhibitor (JSH-23) regardless of the stimulation of CD155 and CD3 (Fig 3G) . Taken together, these results suggest that CD155 triggers Ifng gene transcription via NF-kB.
CHS is attenuated in CD155-deficient mice
Th1 cells play an important role in CHS (32) . Because CD155-mediated costimulatory signaling is involved in Th1 development, we investigated whether CD155 deficiency affects the development of CHS. WT and Pvr 2/2 mice were sensitized by using epicutaneous application of DNCB and then were challenged with DNCB on the left ear and medium alone on the right ear. The net swelling in the left ear, as determined by the difference in the thicknesses of the left and right ears, of both WT and Pvr 2/2 mice was increased at 24 h after antigenic challenge. However, swelling was significantly greater in WT than Pvr 2/2 mice (Fig. 4A ).
Supporting these results, histological analysis demonstrated that the ear swelling at 24 h after application of DNCB was considerably greater in WT mice than in Pvr 2/2 mice (Fig. 4B ). (Fig. 4C) . These results suggest that CD155 on CD4 + T cells is solely responsible for the development of CHS. Because DNAM-1, encoded by Cd226 gene, was expressed on DC (Supplemental Fig. 1C (Fig. 4C) . These results suggest that DNAM-1 on DC plays an important role in the development of CHS as a ligand for CD155.
To confirm the role of CD155 in Th1 development during CHS, the draining lymph nodes were harvested and cytokine production was analyzed 5 d after DNCB sensitization. Flow cytometric analyses showed that the generation of IFN-g-producing CD4 + T cells was impaired in Pvr 2/2 mice compared with WT mice (Fig. 4D, 4E) . However, the generation of IL-4-and IL-17-producing CD4 + T cells was comparable between WT and Pvr 2/2 mice. These results indicate that CD155 is involved in the priming phase of Th1 responses after sensitization with DNCB.
CD155 deficiency enhances allergic airway inflammation
We further investigated whether CD155 deficiency reciprocally augments Th2 responses in vivo. Because CD4 + T cells derived from BALB/c mice similarly showed Th1 development after stimulation with anti-CD155 mAb together with anti-CD3 mAb (Fig. 5A) , we examined allergic airway inflammation in WT or Pvr 2/2 BALB/c mice after immunization i.p. with OVA plus alum and then challenge intranasally with OVA. Pvr 2/2 mice showed significantly higher concentration of serum IgE than did WT mice on day 14 after the immunization. However, there were no differences in IgG1 and IgG2a levels between WT and Pvr 2/2 mice after the immunization (Fig. 5B) . Pvr 2/2 mice exhibited higher numbers of eosinophils in bronchoalveolar lavage fluids (Fig. 5C ) and infiltrated inflammatory cells in the lung (Fig. 5D ), compared with WT mice, after challenge of OVA. Moreover, the frequency of IL-4-and IL-13-producing cells among total CD4 + T cells in the spleen from Pvr 2/2 mice was significantly increased, compared with that from WT mice (Fig. 5E ). Taken together, these results suggest that CD155-mediated signal stimulates Th1 pathway and reciprocally suppresses Th2 development both in vitro and in vivo.
Treatment with anti-CD155 mAb suppresses CHS responses
To investigate whether CD155 is a potential molecular target for preventive and therapeutic applications, we treated mice with a neutralizing anti-CD155 mAb, which blocks the interaction between CD155 and DNAM-1 (28), at 2 h before sensitization or challenge with DNCB (Fig. 6A) . Suppression of ear swelling was greater in mice that received anti-CD155 mAb before sensitization than in mice that received control mAb (Fig. 6B, 6C) . Similarly, administration of anti-CD155 mAb before challenge significantly suppressed CHS responses (Fig. 6D, 6E ), suggesting that CD155 may be a candidate target for therapeutic approaches for ACD.
CD155 is involved in Th1 development in humans
We next examined the expression of CD155 on human PBMCs. Whereas CD155 was expressed abundantly on monocytes, it was scarcely detectable on lymphoid cells, including CD4 + and CD8 + T cells and NK cells (Supplemental Fig. 3A) . However, activation of CD4 + T cells through stimulation with anti-CD3 plus anti-CD28 mAbs markedly upregulated the expression of CD155 (Supplemental Fig. 3B ). To investigate whether CD155 is involved in Th1 development in human, we purified CD4 + CD45RA hi CD45RO 2 naive T cells from the cord blood, stimulated them with anti-CD3 mAb and either anti-CD155 or control Ig, and analyzed subsequent cytokine production. The concentration of IFN-g, but not IL-4 or IL-17, in the culture supernatants of naive CD4 + T cells that had been stimulated with anti-CD155 plus anti-CD3 was significantly higher than that in supernatants from cells stimulated with control Ig plus anti-CD3 (Fig. 7) . These results indicate that CD155 on CD4 + T cells plays an important role in the development of Th1 cells in humans as in mice.
Discussion
CD155 initially was identified as a receptor for poliovirus that was expressed on human epithelial cells (13) . Although mice are not infected with poliovirus, we previously identified the mouse counterpart of CD155 (33) . CD155 is expressed on various hematopoietic and nonhematopoietic cells in both humans and mice. However, the physiological function of CD155, particularly in hematopoietic cells, is incompletely understood. We previously demonstrated that DNAM-1, which is a counterreceptor for CD155 and is expressed also on CD4 + T cells, mediates an activating signal for Th1 development in naive CD4 + T cells in human (30) . In agreement with this context, Lozano et al. (34) suggested that DNAM-1 on CD4 + naive T cells mediates an activating signal for Th1/Th17 differentiation as a result of ligation with CD155. In sharp contrast, the present study demonstrated that CD155 itself mediates a costimulatory signal in CD4 + T cells that promotes Th1 development. These results were further supported by the in vivo study, which showed that whereas CHS was significantly greater in Rag1 Th1 development is induced through both IL-12-dependent and -independent mechanisms (12) . In the present study, we showed that CD155-mediated Th1 development does not require IL-12. Previous reports demonstrated that the costimulatory molecule LFA-1 is involved in Th1 development in an IL-12-independent manner (30, 35) , in which Erk phosphorylation is sustained for .30 min. The sustained phosphorylation of Erk downregulates GATA-3 but upregulates T-bet, resulting in Th1 development from naive CD4 + T cells (30, 35) . CD27, a member of the TNF receptor family, mediates another costimulatory signal that induces Th1 differentiation in an IL-12-independent manner (36, 37) , although the molecular mechanisms underlying this effect remain undetermined as yet. Although we showed that the CD155-mediated costimulatory signal also enhances Erk phosphorylation, Erk was dephosphorylated in several minutes in our experiments (Fig. 1B) . Therefore, CD155 is involved in Th1 development by a mechanism distinct from LFA-1. Instead, we showed that CD155 induced Th1 development in an autocrine IFN-g-dependent manner. CD155 also induced NF-kB activation, which was independent of IFN-g. Evidence demonstrated that p50 and p60 NF-kB subunits bind to the IFN-g promoter and upregulate IFN-g expression (38) . Therefore, CD155 signaling induces IFN-g secretion via NF-kB, leading to autocrine IFN-g-dependent STAT1 activation and the subsequent upregulation of T-bet expression (Supplemental Fig.  4 ). Previous reports also demonstrated that CD155 recruits the Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP-2), which activates MAPK (39, 40) . How CD155 activates NF-kB is unknown currently but SHP-2 might also be involved in NF-kB activation in CD4 + T cells. A recent study has demonstrated that the CD155 promoter region contains an NF-kB binding site (41) , suggesting a positive feedback loop in which CD155 and NF-kB stimulate each other.
The costimulatory signal mediated by CD155 induced Th1 development from naive CD4 + T cells in both humans and mice and exacerbated Th1-mediated CHS and ameliorated Th2-mediated airway inflammation in mice. We showed that treatment with anti-CD155 mAb dampened CHS. Treatment with anti-LFA-1 mAb has been reported to similarly inhibit the development of CHS (42) . However, although LFA-1 also mediates a costimulatory signal that leads to Th1 development from naive CD4 + T cells, mice deficient in LFA-1 or treatment of mice with anti-LFA-1 mAb show impaired migration of T cells to draining lymph nodes (43) , leading to overall T cell dysfunction. In contrast, we observed that cell migration to draining lymph nodes was not impaired in CD155-deficient mice, suggesting that CD155 is not involved in T cell migration into lymph nodes. Notably, treatment with anti-CD155 mAb was effective when injected after as well as before sensitization with DNCB Ag. These characteristics of anti-CD155 treatment are advantageous for its clinical use in the prevention of ACD, because most patients have been already sensitized to a specific allergen. CD155 cooperates the TCR signaling and promotes NFkB activation (1), which then induces Ifng transcription (2). IFN-g binds to IFN-g receptor (3) and induces STAT1 activation (4), followed by transcription of Tbx21 (5), which encodes T-bet, the master regulator of Th1 development. 
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